Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF CAPTOPRIL ON MYOCARDIAL PROTECTION DURING CARDIOPLEGIA
Autore:
DIPASQUALE P; PATERNA S; VALENZA M; VALDES L; ALBANO V; TROMBINO G; VITRANO G; CANNIZZARO S; LICATA G; ALBIERO R;
Indirizzi:
GF INGRASSIA HOSP,DEPT CARDIOL,VIA VAL PLATANI 3 I-90144 PALERMO ITALY UNIV PALERMO,DEPT MED PATHOL 1 PALERMO ITALY UNIV PALERMO,INST PHARMACOL PALERMO ITALY CITY HOSP PALERMO ITALY
Titolo Testata:
International journal of cardiology
fascicolo: 3, volume: 42, anno: 1993,
pagine: 225 - 230
SICI:
0167-5273(1993)42:3<225:EOCOMP>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
INFARCTION; REPERFUSION; INHIBITOR; HEARTS;
Keywords:
CAPTOPRIL; MYOCARDIAL PROTECTION; REPERFUSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
P. Dipasquale et al., "EFFECTS OF CAPTOPRIL ON MYOCARDIAL PROTECTION DURING CARDIOPLEGIA", International journal of cardiology, 42(3), 1993, pp. 225-230

Abstract

The study aimed at checking effects exerted by captopril (C) on humanmyocardial ACE system as well as the role played by tissue ACE inhibition in reducing reperfusion damage. A human experimental model was used during cardioplegia due to aorto-coronary-by-pass (CABG). Fifty-four patients with coronary artery disease affecting 3 vessels having suffered from acute myocardial infarction anterior (AMI-ant), homogenous as far as ejection fraction (35-55%), number of grafts (3), clamping time, age and sex, were randomised in a double blind experiment, and were given captopril of placebo (P). A total of 4 mg/l Captopril was mixed into the cardioplegic solution with blood according to the method of Buckberg (Buckberg GD. J Thorac Cardiovasc Surg 1987; 93: 127-139). Eight samples (blood/perfusate) were obtained from each patients and norepinephrine (NE), epinephrine (E) were assayed using an HPLC technique. Angiotensin I was assayed by RIA. CK was also assayed (units/ml). Blood/perfusate samples were taken during CABG: (1) pre-pump; (2)pump sample; (3) pump preclamping; (4) pump preclamping; (4) coronary sinus; (5)coronary sinus sample during reperfusion; (6) coronary sinus during warm reperfusion; (7) after clamping sample; (8) after decanulation; Results: Captopril group (29 patients): angiotensin I: (1) 8.15; (2)7.0; (4) 8.45; (5) 8.93 (6) 8.73; (7) 9.07; (8) 9.40; versus placebo:(1) 7.09, (2) 7.43; (3) 7.80; (4) 9.31; (5) 9.01; (6) 8.35; (7) 8.85;(8) 8.07; ng/ml, probability, not significant. NE: captopril group: (1) 359; (2) 404; (3) 333; (4) 296; (5) 263; (6) 216; (7) 310; (8) 337;vs. placebo: (1) 408; (2) 437; (3) 422; (4) 371; (5) 494; (6) 530; (7) 464; (8) 399; pg/ml (P < 0.01). CK, captopril group: (1) 79; (2) 95;(3) 100; (4) 94; (5) 104; (6) 94; (7) 108; (8) 108; vs. placebo: (1) 76; (2) 120; (3) 135; (4) 152 (5) 225; (6) 272; (7) 247; (8) 228; units/ml. (P < 0.01). E values showed no significant difference between the two groups. The decrease in NE and CK and increase in angiotensin I in treated patients as compared with controls suggest some effects exerted by captopril on ACE-T and its ability of reducing reperfusion damage and recommeds its use for heart protection during CABG.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/11/20 alle ore 20:24:42